GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Patients with Small Cell Lung Cancer, Sarcoma and Malignant Melanoma will be treated with
GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two
separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability